Companies invest billions in research and development every year. In the US alone, business R&D expenditure exceeded $780 billion in 2024. In the UK, business R&D spending topped £44.5 billion. These investments create proprietary technology, software platforms, trade secrets, patents, datasets, and process innovations — all of which are intangible assets that drive competitive advantage and enterprise value.
Yet most of this investment never appears on the balance sheet. Under both US GAAP (ASC 730) and IFRS (IAS 38), the majority of R&D spending is expensed as incurred. The assets it creates are invisible to anyone reading the financial statements.
This is the balance sheet blind spot, and it has real consequences for founders preparing for exits, CFOs seeking to communicate value to investors, and acquirers trying to understand what they are actually buying.
R&D spending creates intangible capital — proprietary technology, software, patents, trade secrets, and know-how — that drives 60-70% of enterprise value. But under standard accounting rules, most of this investment is expensed immediately, creating a persistent gap between what a company is worth and what its balance sheet shows.
The accounting treatment of R&D reflects a decades-old caution about the uncertainty of future benefits from research activities. The logic is straightforward: because the outcome of research is uncertain, the costs should be expensed rather than capitalised as assets.
The specific rules differ between US GAAP and IFRS, and understanding the differences matters — especially for companies operating across jurisdictions or considering cross-border transactions.
| Dimension | US GAAP (ASC 730) | IFRS (IAS 38) |
|---|---|---|
| Research costs | Expensed as incurred | Expensed as incurred |
| Development costs | Expensed as incurred (with narrow exceptions for software under ASC 985-20 and ASC 350-40) | Capitalised when six criteria are met: technical feasibility, intention to complete, ability to use or sell, probable future benefits, adequate resources, reliable measurement |
| Software development | Internal-use: capitalise after preliminary project stage (ASC 350-40). External-sale: capitalise after technological feasibility (ASC 985-20) | Capitalise when IAS 38 development criteria are met |
| Balance sheet recognition | Minimal — most R&D appears only as an expense | Potentially significant — development costs meeting the criteria appear as intangible assets |
| Result | Almost all R&D is invisible on the balance sheet | Some development costs appear, but research costs are still expensed |
IFRS is more permissive than US GAAP in allowing capitalisation of development costs. This means that the same company, reporting under different standards, will show different asset values — even though the underlying economic reality is identical. An IFRS-reporting company may show millions in capitalised development costs that a US GAAP-reporting company would have expensed entirely.
The practical effect is that most technology companies — particularly those in the US — carry significant unrecognised intangible assets that were created by R&D investment but never recorded on the balance sheet.
R&D spending does not disappear into a void. It produces specific, identifiable categories of intangible assets. Understanding what your R&D creates — and mapping expenditure to asset categories — is the first step toward measuring and communicating the value it generates.
| R&D Activity | Intangible Asset Created | Example |
|---|---|---|
| Product development | Proprietary technology | A SaaS company's core platform architecture |
| Software engineering | Software assets | Internal tools, customer-facing applications, APIs |
| Algorithm design | Proprietary algorithms | Machine learning models, pricing engines, recommendation systems |
| Patent filings | Patents and IP | Granted patents, pending applications |
| Process improvement | Trade secrets and know-how | Manufacturing processes, operational playbooks |
| Data collection and structuring | Data assets | Proprietary datasets, training data, customer intelligence |
| Clinical trials and testing | Regulatory approvals and in-process R&D | FDA approvals, CE marking, drug pipelines |
Break down your total R&D spend by activity type: product development, software engineering, research, testing, data collection, and process improvement. Most companies track R&D as a single line item — disaggregating it reveals the asset categories being built.
Using the table above as a starting point, assign each R&D activity to one or more intangible asset categories. A single engineering sprint may create software assets, proprietary technology, and data assets simultaneously.
For each asset category, estimate the useful life and the revenue or cost-savings contribution. A patent may have a 20-year legal life but a 5-year economic life if technology cycles are short. A proprietary dataset may appreciate in value as it grows.
Build a register of intangible assets created by R&D, with cumulative investment totals, useful life estimates, and contribution metrics. This register becomes the foundation for intangible asset valuation, exit preparation, and investor communication.
When a company is acquired, the buyer performs a purchase price allocation (PPA) that identifies and values the intangible assets embedded in the purchase price. Suddenly, the R&D that was expensed for years appears on the acquirer's balance sheet as identified intangible assets — often at values that surprise both parties.
A private equity firm acquires a B2B SaaS company for $50 million. The target's balance sheet shows $3 million in total assets, mostly cash and receivables. The PPA identifies $18 million in customer relationships, $12 million in proprietary technology, $4 million in brand value, and $3 million in software assets — for a total of $37 million in identifiable intangible assets. The remaining $10 million is allocated to goodwill. All of this intangible value was created by years of R&D investment that never appeared on the seller's balance sheet.
This is not an unusual outcome. In technology acquisitions, identified intangible assets routinely represent 50-80% of the purchase price. The gap between the seller's book value and the acquisition price is almost entirely attributable to intangible capital created by R&D, marketing, and human capital investment.
The implication for founders and CFOs is straightforward: if you wait until the acquisition to discover the value of your intangible assets, you have already lost negotiating leverage. Measuring and documenting that value proactively — before the exit process begins — gives you a stronger position at the table.
The tax treatment of R&D varies significantly between jurisdictions, and the recent legislative changes in both the US and UK have made the landscape more complex.
| Dimension | United States | United Kingdom |
|---|---|---|
| Current expensing rule | Section 174A (OBBBA, 2025): full immediate expensing for domestic R&D | RDEC (large companies): 20% above-the-line credit on qualifying R&D spend |
| Prior rule (2022-2024) | Section 174 (TCJA): 5-year amortization for domestic, 15-year for foreign | Enhanced Deduction (SMEs): 86% additional deduction, or 14.5% credit if loss-making |
| Retroactive relief | Small businesses (under $31M gross receipts) can amend 2022-2024 returns by July 6, 2026 | No retroactive changes — claims made in the year R&D is incurred |
| Foreign R&D | Still amortized over 15 years under Section 174 | Qualifying overseas expenditure included in RDEC claims (with conditions) |
| Interaction with credits | Section 280C coordination required when R&D credit (Section 41) and deduction both claimed | No equivalent coordination issue — RDEC is a standalone credit |
| Balance sheet impact | R&D expensed (US GAAP/ASC 730); tax deduction does not create a balance sheet asset | Some development costs capitalised (IFRS/IAS 38); RDEC credit reduces tax charge |
UK companies reporting under IFRS may capitalise development costs that meet the IAS 38 criteria, creating a balance sheet asset for some R&D expenditure. US companies reporting under ASC 730 generally cannot. This means that the same R&D investment can look very different on the balance sheet depending on which standard is applied — a consideration for cross-border transactions, dual-listed companies, and international investors comparing targets.
The gap between R&D expenditure and balance sheet recognition creates a systematic understatement of enterprise value in traditional accounting-based valuations. This matters in three specific contexts.
When preparing for a sale, the seller's intangible assets are the primary driver of the valuation multiple. A company with well-documented intangible assets — mapped to specific categories, with estimated useful lives and contribution metrics — commands a higher multiple than a company that simply reports R&D as an expense line. Buyers pay for clarity and certainty. Documenting your intangible asset portfolio reduces perceived risk and supports a premium valuation.
Investors — whether venture capital, private equity, or strategic — increasingly understand that intangible assets drive value. Presenting your R&D investment as an intangible asset portfolio, rather than a cost centre, changes the conversation from "why are you spending so much on R&D" to "how are you building defensible competitive advantages."
A growing segment of the lending market uses intangible assets as collateral. R&D-intensive companies that can identify and value their intangible asset portfolio — including patents, software, and proprietary technology — may access IP-backed financing that would not be available to companies relying solely on traditional collateral.
The Opagio growth platform provides a structured framework for mapping R&D expenditure to intangible asset categories using the Opagio 12 value driver taxonomy. Rather than treating R&D as a single expense line, the platform helps companies:
The Opagio Valuator provides a starting point for estimating the value of your intangible asset portfolio. For companies preparing for an exit or a funding round, the Opagio Calculator models specific valuation scenarios using your actual financial data.
R&D is not a cost to be minimised — it is an investment in intangible capital that creates long-term competitive advantage and enterprise value. The companies that measure, track, and communicate their intangible asset portfolio consistently achieve better outcomes in exits, fundraising, and strategic positioning.
Whether you are a US company navigating the Section 174A changes, a UK company optimising your RDEC claims, or a growth-stage company preparing for its next milestone, the practical steps are the same:
If I expense R&D for tax purposes, does it still count as an intangible asset? Yes. Tax treatment and economic reality are different concepts. Expensing R&D for tax purposes (as restored by Section 174A in the US) reduces your tax liability but does not change the fact that the R&D created intangible assets — technology, software, patents, trade secrets — that have economic value and drive your company's worth.
Does capitalising development costs under IAS 38 make my company look more valuable? It increases the reported asset value on the balance sheet, but it also means the asset will be amortised over its useful life, creating ongoing charges in the income statement. The capitalisation decision should be driven by the accounting criteria, not by a desire to inflate the balance sheet. Investors and acquirers see through cosmetic capitalisation.
How does intangible asset mapping help in fundraising? It changes the narrative from "we spend a lot on R&D" to "we have built a portfolio of defensible intangible assets worth X." Investors respond to specificity. Showing that your R&D has created $5 million in proprietary technology, $3 million in data assets, and $2 million in patents is more compelling than reporting $10 million in cumulative R&D expense.
Ivan Gowan is the Founder and CEO of Opagio. With 25 years in financial technology — including 15 years at IG Group where he helped grow the company from £300m to £2.7bn in market capitalisation — Ivan has first-hand experience of how R&D investment creates massive intangible value that traditional accounting fails to recognise. Opagio exists to close that gap. Meet the team.
The One Big Beautiful Bill Act restored full R&D expensing under new Section 174A for tax years beginning 2025. Small businesses can retroactively reclaim deductions for 2022-2024. Here is what changed, who qualifies, and what the July 6 2026 deadline means for your company.
Read more →A step-by-step guide to filing retroactive R&D expense claims under Section 174A of the OBBBA. Covers eligibility, the amended return process, Section 280C coordination, and practical examples of tax impact — all before the July 6, 2026 deadline.
Read more →
IAS 38 hasn't kept pace with the intangible economy. Here's what the IASB, CSRD, and FRC are doing and how companies should prepare for reporting changes.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Book a free consultation to see how the Opagio Growth Platform can help your business.